NCT03904563View on ClinicalTrials.gov

Bevacizumab After Chemoradiotherapy For Locally Advanced Lung Adenocarcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 1, 2019

Primary Completion Date

December 10, 2021

Study Completion Date

December 15, 2022

Conditions
Lung Adenocarcinoma
Interventions
DRUG

Bevacizumab

Patients are treated with Bevacizumab 1-2 months after the chemoradiotherapy.The recommended dose for intravenous infusion is 15mg/kg body weight, which is given every 3 weeks for up to 1 year.

RADIATION

chest radiation

split-course chest radiation

DRUG

concurrent chemotherapy

weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation

Trial Locations (1)

510000

Sun yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT03904563 - Bevacizumab After Chemoradiotherapy For Locally Advanced Lung Adenocarcinoma | Biotech Hunter | Biotech Hunter